REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

REGENXBIO Inc. (Nasdaq: RGNX) has announced upcoming presentations of new interim data for ABBV-RGX-314 at the American Academy of Ophthalmology 2024 annual meeting.

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced upcoming presentations of new interim data for ABBV-RGX-314 at the American Academy of Ophthalmology 2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for treating wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other chronic retinal conditions.

The presentations will include:

• New results from a bilateral dosing study using subretinal delivery for wet AMD
• Data from a Phase 2 dose-escalation study evaluating suprachoroidal delivery for diabetic retinopathy
• Long-term follow-up results from the Phase I/IIa subretinal delivery program in wet AMD

These presentations will provide insights into the potential efficacy and safety of ABBV-RGX-314 across different delivery methods and retinal conditions.

Positive

• Presentation of new interim data for ABBV-RGX-314 at a major ophthalmology conference
• Ongoing collaboration with AbbVie for development of ABBV-RGX-314
• Multiple presentations covering different delivery methods and indications for ABBV-RGX-314

Negative

• None.

Argus Session date unavailable

+4.72% session move Open Argus

Details

News Market Reaction – RGNX

The recorded move for RGNX in the trading session of this news was +4.72%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology 2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.

New data will be presented as follows:

Title: Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study (abstract 30080148)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Saturday, October 19, 2024, at 11:59 a.m. ET

Encore presentations will be presented as follows:

Title: A Phase 2 Dose-Escalation Study Evaluating Suprachoroidal Delivery of Investigational ABBV-RGX-314 Gene Therapy for DR (abstract 30078795)
Presenter: Arshad Khanani M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates
Date/Time: Monday, October 21, 2024, at 10:45 a.m. ET

Title: Long-Term Follow-Up Study Results from the Investigational Phase I/IIa ABBV-RGX-314 Subretinal Delivery Gene Therapy Program in nAMD (abstract 30079480)
Presenter: Philip P. Storey, M.D., Austin Retina Associates
Date/Time: Monday, October 21, 2024, at 12:45 p.m. ET

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Zolgensma^® is a registered trademark of Novartis Gene Therapies.

Contacts:
Dana Cormack
Corporate Communications
DCORMACK@regenxbio.com 

George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024-annual-meeting-302280013.html

SOURCE REGENXBIO Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is ABBV-RGX-314 and what conditions is it being developed to treat?

ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed by REGENXBIO in collaboration with AbbVie. It is being studied for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other chronic retinal conditions.

What new data will REGENXBIO (RGNX) present at the American Academy of Ophthalmology 2024 meeting?

REGENXBIO will present new interim data on subretinal delivery of ABBV-RGX-314 in patients with bilateral wet AMD, results from a Phase 2 dose-escalation study using suprachoroidal delivery for diabetic retinopathy, and long-term follow-up results from the Phase I/IIa subretinal delivery program in wet AMD.

When and where will REGENXBIO (RGNX) present the new ABBV-RGX-314 data in October 2024?

REGENXBIO will present the new ABBV-RGX-314 data at the American Academy of Ophthalmology 2024 annual meeting. The presentations are scheduled for October 19 and October 21, 2024, at various times during the conference.